Pre-made Depatuxizumab Mafodotin benchmark antibody (Whole mAb ADC, anti-EGFR therapeutic antibody, Anti-ERBB/ERBB1/ERRP/HER1/NISBD2/PIG61/mENA Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Depatuxizumab Mafodotin benchmark antibody (Whole mAb ADC, anti-EGFR therapeutic antibody, Anti-ERBB/ERBB1/ERRP/HER1/NISBD2/PIG61/mENA Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Depatuxizumab mafodotin (INN; development code ABT-414) is an antibody-drug conjugate designed for the treatment of cancer.[1][2] It is composed of an EGFR IGg1 monoclonal antibody (depatuxizumab) conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link.[3][4]
| Products Name (INN Index) | Pre-Made Depatuxizumab Mafodotin Biosimilar, Whole Mab Adc, Anti-Egfr Antibody: Anti-ERBB/ERBB1/ERRP/HER1/NISBD2/PIG61/mENA therapeutic antibody Drug Conjugate |
|---|---|
| INN Name | depatuxizumab mafodotin |
| Target | EGFR |
| Format | Whole mAb ADC |
| Derivation | Chimeric Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – kappa |
| VD LC | IgG1 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | AbbVie?Inc. (North Chicago IL USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | EGFR |
| Package |
